title: Inhibitory effect of arctigenin on lymphocyte activation stimulated with PMA/ionomycin.
abstract: This study investigated the effect of arctigenin (Arc) on the cell activation, cytokines expression, proliferation, and cell-cycle distribution of mouse T lymphocytes. Mouse lymphocytes were prepared from lymph node and treated with Phorbol-12-myristate-13-acetate (PMA)/Ionimycin (Ion) and/or Arc. CD69, CD25, cytokines, proliferation and cell cycle were assayed by flow cytometry. The results showed that, at concentrations of less than 1.00 micromol x L(-1), Arc expressed non-obvious cell damage to cultured lymphocytes, however, it could significantly down-regulate the expression of CD69 and CD25, as well as TNF-alpha, IFN-gamma, IL-2, IL-4, IL-6 and IL-10 on PMA/Ion stimulated lymphocytes. At the same time, Arc could also inhibit the proliferation of PMA/Ion-activated lymphocytes and exhibited lymphocyte G 0/G1 phase cycle arrest. These results suggest that Arc possesses significant anti-inflammatory effects that may be mediated through the regulation of cell activation, cytokines expression and cell proliferation.
authors: Cheng-Hong
authors: CH
authors: Sun
authors: Xin-Qiang
authors: XQ
authors: Lai
authors: Li
authors: L
authors: Zhang
authors: Jing-Chun
authors: JC
authors: Yao
authors: Yong-Xia
authors: YX
authors: Guan
authors: Li-Hong
authors: LH
authors: Pan
authors: Ying
authors: Y
authors: Yan
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000302:isolation & purification / Q000494:pharmacology*; D015703:Antigens, CD / Q000378:metabolism; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism; D031170:Arctium / Q000737:chemistry; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D016207:Cytokines / Q000378:metabolism*; D005260:Female; D005663:Furans / Q000302:isolation & purification / Q000494:pharmacology*; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D015759:Ionomycin / Q000494:pharmacology; D037181:Lectins, C-Type / Q000378:metabolism; D017705:Lignans / Q000302:isolation & purification / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D010946:Plants, Medicinal / Q000737:chemistry; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000099192:CD69 Antigens
chemical_list: D000893:Anti-Inflammatory Agents; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D016207:Cytokines; D005663:Furans; D007371:Interferon-gamma; D016753:Interleukin-10; D007376:Interleukin-2; D053645:Interleukin-2 Receptor alpha Subunit; D015847:Interleukin-4; D015850:Interleukin-6; D015759:Ionomycin; D037181:Lectins, C-Type; D017705:Lignans; D013755:Tetradecanoylphorbol Acetate; D014409:Tumor Necrosis Factor-alpha; D000099192:CD69 Antigens; C071942:arctigenin